Skip to main content
    O

    Omeros Corporation (OMER)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.68
    -0.81 (-4.63%)

    Market Cap: $1.27B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Omeros Corporation (OMER) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Omeros are Oric Pharmaceuticals (ORIC), Olema Pharmaceuticals (OLMA) and OmniAb (OABI). By market cap, Omeros ranks 7th of the 13 companies on this page; Harmony Biosciences Holdings (HRMY) is the largest at $1.98B.

    Peer Comparison

    OMER's ROIC of 33.6% is above the peer median of -16.2%, and its revenue growth of 14.9% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Omeros (OMER)$1.27BN/A16.4x324.9%33.6%14.9%0.00%
    Oric Pharmaceuticals Inc (ORIC)$814.71MN/AN/A0.0%N/A0.0%0.00%
    Olema Pharmaceuticals Inc (OLMA)$662.30MN/AN/A0.0%-53.8%0.0%0.00%
    OmniAb Inc. (OABI)$716.17MN/A15.7x-108.1%-17.5%78.3%0.00%
    Ocular Therapeutix Inc (OCUL)$1.37BN/A26.9x0.0%-52.1%-11.5%0.00%
    Harmony Biosciences Holdings (HRMY)$1.98B9.6x1.9x18.0%13.7%12.3%0.00%
    Zenas BioPharma, Inc. Common Stock (ZBIO)$1.90BN/A168.0x0.0%-104.3%-100.0%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Corvus Pharmaceuticals Inc (CRVS)$897.52MN/AN/A0.0%N/A0.0%0.00%
    Ultragenyx (RARE)$1.64BN/A2.2x-71.8%N/A8.1%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Geron Corporation (GERN)$622.98MN/A2.9x-22.0%-7.4%27.4%0.00%
    MannKind Corp (MNKD)$1.33BN/A3.1x-18.1%-10.4%24.0%0.00%
    Peer median$1.11B9.6x3.1x0.0%-16.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Omeros, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Oric Pharmaceuticals Inc (ORIC)
    ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers.
    ORIC competitors
    Olema Pharmaceuticals Inc (OLMA)
    Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development...
    OLMA competitors
    OmniAb Inc. (OABI)
    OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform.
    OABI competitors
    Ocular Therapeutix Inc (OCUL)
    Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development...
    OCUL competitors
    Harmony Biosciences Holdings (HRMY)
    Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders.
    HRMY competitors
    Zenas BioPharma, Inc. Common Stock (ZBIO)
    Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based...
    ZBIO competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    Corvus Pharmaceuticals Inc (CRVS)
    Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
    CRVS competitors
    Ultragenyx (RARE)
    Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development...
    RARE competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Geron Corporation (GERN)
    Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic...
    GERN competitors
    MannKind Corp (MNKD)
    MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung...
    MNKD competitors

    Frequently Asked Questions About OMER

    Who are Omeros' main competitors?

    The companies most similar to Omeros include Oric Pharmaceuticals (ORIC), Olema Pharmaceuticals (OLMA), OmniAb (OABI), Ocular Therapeutix (OCUL) and Harmony Biosciences Holdings (HRMY), listed from the closest match.

    Who is Omeros' biggest competitor?

    Harmony Biosciences Holdings (HRMY) is the largest of the similar companies at $1.98B; Oric Pharmaceuticals (ORIC) is the closest match by business profile, size, sector and industry.

    How does OMER stock compare with its competitors?

    OMER's P/S is 16.4x against a peer median of 3.1x; its net margin is 324.9% against a peer median of 0.0%.

    Which of Omeros' competitors pays a higher dividend?

    Omeros pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Omeros bigger than its competitors?

    No. Omeros is 7th by market cap among the 13 companies on this page; the largest is Harmony Biosciences Holdings (HRMY) at $1.98B.